[go: up one dir, main page]

CY1120021T1 - Σκευασματα δεφερασιροξης χορηγηση απο του στοματος - Google Patents

Σκευασματα δεφερασιροξης χορηγηση απο του στοματος

Info

Publication number
CY1120021T1
CY1120021T1 CY20181100302T CY181100302T CY1120021T1 CY 1120021 T1 CY1120021 T1 CY 1120021T1 CY 20181100302 T CY20181100302 T CY 20181100302T CY 181100302 T CY181100302 T CY 181100302T CY 1120021 T1 CY1120021 T1 CY 1120021T1
Authority
CY
Cyprus
Prior art keywords
oral administration
transferral
preparations
neutral
release
Prior art date
Application number
CY20181100302T
Other languages
English (en)
Inventor
Indrajit Ghosh
Jia-Ai Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120021(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1120021T1 publication Critical patent/CY1120021T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Αποκαλύπτονται σκευάσματα δεφερασιρόξης για χορήγηση από του στόματος τα οποία έχουν μειωμένη απελευθέρωση στις συνθήκες του στομάχου και ταχεία απελευθέρωση σε σχεδόν ουδέτερο pΗ ή σε ουδέτερο pΗ.
CY20181100302T 2013-03-08 2018-03-12 Σκευασματα δεφερασιροξης χορηγηση απο του στοματος CY1120021T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361774893P 2013-03-08 2013-03-08
US201361824435P 2013-05-17 2013-05-17
EP14710654.6A EP2964202B2 (en) 2013-03-08 2014-03-06 Oral formulations of deferasirox

Publications (1)

Publication Number Publication Date
CY1120021T1 true CY1120021T1 (el) 2018-12-12

Family

ID=50288212

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100302T CY1120021T1 (el) 2013-03-08 2018-03-12 Σκευασματα δεφερασιροξης χορηγηση απο του στοματος
CY20191100143T CY1121315T1 (el) 2013-03-08 2019-01-31 Απο του στοματος χορηγουμενες συνθεσεις της δεφερασιροξης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191100143T CY1121315T1 (el) 2013-03-08 2019-01-31 Απο του στοματος χορηγουμενες συνθεσεις της δεφερασιροξης

Country Status (42)

Country Link
US (4) US9283209B2 (el)
EP (2) EP3124018B2 (el)
JP (3) JP6434429B2 (el)
KR (2) KR20170045391A (el)
CN (1) CN105025886B (el)
AP (1) AP2015008668A0 (el)
AU (2) AU2014224198B2 (el)
BR (1) BR112015021254A2 (el)
CA (1) CA2890465A1 (el)
CL (1) CL2015002495A1 (el)
CR (1) CR20150467A (el)
CU (1) CU24348B1 (el)
CY (2) CY1120021T1 (el)
DK (2) DK3124018T3 (el)
DO (1) DOP2015000220A (el)
EA (1) EA031719B1 (el)
EC (1) ECSP15042897A (el)
ES (2) ES2663135T5 (el)
HK (1) HK1212242A1 (el)
HR (2) HRP20180387T1 (el)
HU (2) HUE036921T2 (el)
IL (1) IL240797B (el)
JO (1) JO3570B1 (el)
LT (2) LT3124018T (el)
ME (1) ME03297B (el)
MX (1) MX361055B (el)
MY (1) MY170303A (el)
NI (1) NI201500126A (el)
NZ (1) NZ711179A (el)
PE (1) PE20151600A1 (el)
PH (1) PH12015501981A1 (el)
PL (2) PL3124018T3 (el)
PT (2) PT3124018T (el)
RS (2) RS56890B1 (el)
SA (1) SA515360425B1 (el)
SG (2) SG11201506491RA (el)
SI (2) SI2964202T1 (el)
TN (1) TN2015000393A1 (el)
TW (2) TWI625136B (el)
UY (1) UY35367A (el)
WO (1) WO2014136079A1 (el)
ZA (1) ZA201506060B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008668A0 (en) 2013-03-08 2015-08-31 Novartis Ag Oral formulations of deferasirox
US9866684B2 (en) * 2015-02-16 2018-01-09 Microsoft Technology Licensing, Llc Process for real-time data exchange between users on a phone call
WO2016167729A1 (en) * 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
AU2016280280B2 (en) * 2015-06-17 2021-09-02 AustinPx, LLC Improved formulations of deferasirox and methods of making the same
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3481390A4 (en) * 2016-07-05 2020-03-04 Jubilant Generics Limited PHARMACEUTICAL COMPOSITION WITH IMMEDIATE RELEASE OF IRON CHELATE IMAGERS
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
TR201707764A2 (tr) * 2017-05-29 2018-12-21 Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasiroksun bölünebilir tablet formları.
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
WO2022186809A1 (en) * 2021-03-05 2022-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet comprising deferasirox
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
KR20070022243A (ko) * 2004-04-08 2007-02-26 노파르티스 아게 데페라시록스 분산성 정제
KR20080056225A (ko) * 2005-10-19 2008-06-20 노파르티스 아게 데페라시록스를 포함하는 분산성 정제
EP2062572A1 (en) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
WO2009106824A2 (en) 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
US20110097413A1 (en) 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox
WO2010143006A1 (en) 2009-06-10 2010-12-16 Carlo Ghisalberti Orally bioavailable iron chelators in the treatment of an inflammatory bowel disease
WO2012003987A1 (en) * 2010-07-08 2012-01-12 Ratiopharm Gmbh Oral dosage form of deferasirox
CA2812505A1 (en) 2010-10-01 2012-04-05 Cipla Limited Pharmaceutical composition
AP2015008668A0 (en) 2013-03-08 2015-08-31 Novartis Ag Oral formulations of deferasirox
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox

Also Published As

Publication number Publication date
ECSP15042897A (es) 2019-03-29
MY170303A (en) 2019-07-17
MX2015011962A (es) 2016-07-07
RS56890B1 (sr) 2018-04-30
AU2017203897B2 (en) 2019-02-14
NZ711179A (en) 2018-07-27
US20180221285A1 (en) 2018-08-09
US20150017241A1 (en) 2015-01-15
PL3124018T3 (pl) 2018-05-30
HRP20190173T1 (hr) 2019-03-22
EA201591665A1 (ru) 2015-12-30
TW201442742A (zh) 2014-11-16
PH12015501981B1 (en) 2016-01-11
PT3124018T (pt) 2018-03-22
CU24348B1 (es) 2018-05-08
SA515360425B1 (ar) 2018-01-21
KR101925671B1 (ko) 2019-02-27
CN105025886B (zh) 2019-01-15
HUE036921T2 (hu) 2018-08-28
NI201500126A (es) 2015-11-18
PH12015501981A1 (en) 2016-01-11
TW201838623A (zh) 2018-11-01
SG10201807204YA (en) 2018-09-27
KR20150126900A (ko) 2015-11-13
AP2015008668A0 (en) 2015-08-31
HK1212242A1 (en) 2016-06-10
SI2964202T1 (sl) 2019-02-28
TWI625136B (zh) 2018-06-01
DK3124018T3 (en) 2018-03-26
PE20151600A1 (es) 2015-11-26
IL240797A0 (en) 2015-10-29
EP3124018B1 (en) 2017-12-20
CU20150110A7 (es) 2016-04-25
US20160220493A1 (en) 2016-08-04
CY1121315T1 (el) 2020-05-29
EP2964202A1 (en) 2016-01-13
JO3570B1 (ar) 2020-07-05
CN105025886A (zh) 2015-11-04
DOP2015000220A (es) 2015-11-30
ES2708955T3 (es) 2019-04-12
PL2964202T3 (pl) 2019-04-30
TWI686215B (zh) 2020-03-01
UY35367A (es) 2014-10-31
MX361055B (es) 2018-11-26
EP3124018A1 (en) 2017-02-01
AU2014224198A1 (en) 2015-09-10
ES2663135T3 (es) 2018-04-11
AU2017203897A1 (en) 2017-06-29
DK2964202T3 (en) 2019-02-25
US20170290811A1 (en) 2017-10-12
WO2014136079A1 (en) 2014-09-12
ES2663135T5 (en) 2024-12-16
ES2708955T5 (es) 2023-11-10
JP2020180123A (ja) 2020-11-05
BR112015021254A2 (pt) 2017-07-18
EP2964202B1 (en) 2018-10-31
EP3124018B2 (en) 2024-04-24
CA2890465A1 (en) 2014-09-12
LT3124018T (lt) 2018-03-12
SI3124018T1 (en) 2018-04-30
ME03297B (me) 2019-07-20
CR20150467A (es) 2015-10-27
US9283209B2 (en) 2016-03-15
HRP20180387T1 (hr) 2018-04-20
HUE041224T2 (hu) 2019-05-28
EA031719B1 (ru) 2019-02-28
JP2016510068A (ja) 2016-04-04
RS58317B1 (sr) 2019-03-29
IL240797B (en) 2022-01-01
AU2014224198B2 (en) 2017-06-15
TN2015000393A1 (en) 2017-01-03
JP2018162255A (ja) 2018-10-18
LT2964202T (lt) 2019-02-11
CL2015002495A1 (es) 2016-03-04
JP6434429B2 (ja) 2018-12-05
KR20170045391A (ko) 2017-04-26
JP6739470B2 (ja) 2020-08-12
EP2964202B2 (en) 2023-05-31
ZA201506060B (en) 2016-12-21
SG11201506491RA (en) 2015-09-29
PT2964202T (pt) 2019-02-06

Similar Documents

Publication Publication Date Title
CY1120021T1 (el) Σκευασματα δεφερασιροξης χορηγηση απο του στοματος
IL285965A (en) Ex vivo organ care system
HUE059249T2 (hu) Baktériumtörzseket tartalmazó készítmények
DK3525830T3 (da) Pyrrolobenzodiazepin-konjugater
DK3458479T3 (da) Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
PL3595570T3 (pl) System opracowywania zębów do zakładania licówek
EP3380126A4 (en) ANTIBODY-ACTIVE CONJUGATES WITH BRANCHED LINKERS AND ASSOCIATED METHODS
HUE036362T2 (hu) Baktériumtörzseket tartalmazó készítmények
HUE041969T2 (hu) Baktériumtörzseket tartalmazó készítmények
IL268684A (en) Compositions and methods for immunooncology
DK3250237T3 (da) Hemiasterlinderivater til konjugering og terapi
HUE046221T2 (hu) Bakteriális törzseket tartalmazó készítmények
HUE058252T2 (hu) Baktériumtörzseket tartalmazó készítmények
HUE046681T2 (hu) Baktériumtörzseket tartalmazó készítmények
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
HUE054397T2 (hu) Antitestkészítmények daganatkezelésre
DK3270965T3 (da) Cd48-antistoffer og konjugater deraf
DK3334500T3 (da) Multiligand-lægemiddelskonjugater og anvendelser deraf
DK3359107T3 (da) Patientløftesystem
DK3668874T3 (da) Pyrrolobenzodiazepin-konjugater
EP3355931C0 (en) PROTEIN CONJUGATES
HUE053488T2 (hu) Baktériumtörzseket tartalmazó készítmények
HUE055762T2 (hu) Nyújtott hatású készítmények
HUE052319T2 (hu) Baktériumtörzseket tartalmazó készítmények
LT3522905T (lt) Imunogeniniai arginazės peptidai